Vistagen Therapeutics Inc.

Development of drugs for the treatment of CNS diseases and diabetes

Vistagen is a privately-held company founded in 1998 by Dr. Snodgrass, who was Chief Scientific Officer of Progenitor, Inc. The company is a leader in applied stem cell technologies for rapid drug lead prioritisation.
Early 2004, the company has received a $379,000 phase 1 Small Business Innovation Research (SBIR) grant entitled Development of 4-Chlorokynurenine to treat epilepsy. Upon acquiring Artemis Neuroscience the company also received access to its lead drug candidate AV-101.

H. Ralph Snodgrass, Dr., President & CEO
Shawn K. Singh, Chief Strategy Officer, Director
Matthew W. Kalnik, Ph.D., Executive VP, Head of Business Development
A. Franklin Rice, Senior VP, Finance & Administration

Jon S. Saxe, Chairman
Gregory A. Bonfiglio
Stephen J. Williams, PhD

Gordon Keller, Ph.D., Chairman
Allen Cato, MD, PhD
George Clay, PhD
Arthur Fetter, PhD
Jacqueline A. French, MD
Curtis D. Klaassen, Ph.D.
Lynn D. Kramer, MD
Michael Liebman, PhD
Robert Schwarcz, PhD

384 Oyster Point Blvd.
Suite #8
South San Francisco
CA 94080
USA
Phone: +1-650-244-9990
Fax: +1-650-244-9991

Embryonic stem cell technologies for drug development (CNS diseases, diabetes); the lead drug candidate, AV-101, for the treatment of epilepsy is assumed to be more effective and have less serious side effects than current therapies.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.